ATLANTA, June 15 /PRNewswire/ — CorMatrix®
Cardiovascular, a medical device company dedicated to developing
and delivering unique extracellular matrix (ECM) biomaterial
devices that harness the body’s innate ability to repair damaged
cardiovascular tissue, announced today it has received CE mark for
its CorMatrix ECM for Cardiac Tissue Repair. With this designation,
CorMatrix is now able to market this product in European Union
countries.
“This CE mark will allow surgeons in Europe to expand their use of CorMatrix
ECM to patients needing cardiac tissue repair,” said Beecher Lewis,
President and Chief Operating Officer, CorMatrix. “We believe this
additional indication will allow us to significantly expand our
presence outside of the United
States and drive growth in key markets.”
CorMatrix’s ECM for Cardiac Tissue Repair is used to repair
heart structures during open heart surgery – such as closing
a hole in the heart (known as atrial septal defect or ASD). During
surgery, CorMatrix ECM is sutured onto the heart tissue in need of
repair. It then serves as a scaffold, enabling the body’s own cells
to infiltrate and ultimately replace and remodel the implanted ECM
with native tissue. The anatomy is restored naturally through the
course of the body’s innate wound healing process. It works
differently than other available surgical materials, as CorMatrix
ECM allows for repair of damaged tissue without leaving permanent
synthetic or foreign materials in the body, which can result in
unwanted effects.
“Through my experience using CorMatrix ECM for pericardial
closure procedures, we’ve seen that it supports native tissue
repair and provides favorable outcomes for patients,” said Prof.
Giovanni Ste
‘/>”/>
SOURCE
